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SREBP1 drives Keratin-80-dependent cytoskeletal
changes and invasive behavior in endocrine-
resistant ERα breast cancer
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Approximately 30% of ERα breast cancer patients relapse with metastatic disease following
adjuvant endocrine therapies. The connection between acquisition of drug resistance and
invasive potential is poorly understood. In this study, we demonstrate that the type II keratin
topological associating domain undergoes epigenetic reprogramming in aromatase inhibitors
(AI)-resistant cells, leading to Keratin-80 (KRT80) upregulation. KRT80 expression is driven
by de novo enhancer activation by sterol regulatory element-binding protein 1 (SREBP1).
KRT80 upregulation directly promotes cytoskeletal rearrangements at the leading edge,
increased focal adhesion and cellular stiffening, collectively promoting cancer cell invasion.
Shearwave elasticity imaging performed on prospectively recruited patients conﬁrms KRT80
levels correlate with stiffer tumors. Immunohistochemistry showed increased KRT80-positive
cells at relapse and, using several clinical endpoints, KRT80 expression associates with poor
survival. Collectively, our data uncover an unpredicted and potentially targetable direct link
between epigenetic and cytoskeletal reprogramming promoting cell invasion in response
to chronic AI treatment.
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Aromatase inhibitors (AI) treatment is standard of care forbreast cancer (BC), yet BC cells frequently display drug-resistance and stronger metastatic potential at relapse,
suggesting that chronic exposure to endocrine treatment might
contribute in shaping the invasive potential, as suggested by
previous in vitro studies1,2. The mechanism/s, order of events
and molecular players mediating these phenomena are not well
understood but it is likely that they involve cytoskeletal re-
arrangements as they are essential for cancer invasion and
metastasis3. One possibility is that endocrine therapies (ET)
might indirectly promote invasive behaviors by selecting for
interrelated phenotypes during tumor evolution4–6. Alternatively,
AI treatment may directly contribute to the activation of
invasive transcriptional programs. Chronic exposure to ET leads
to coordinated activation and decommissioning of regulatory
regions such as enhancer and promoters as shown by global
changes in the localization of epigenetic marks H3K27ac and
H3K4me1-26,7,8. These epigenetic changes occasionally involve
entire topological associating domains (TADs), three-
dimensional compartments within the genome thought to
restrict enhancer-promoter interactions9,10. In this manuscript,
we show how drug-induced epigenetic reprogramming leads to
signiﬁcant cytoskeletal changes and mechano-properties at the
cellular level to promote invasive behavior.
Results
Epigenetic reprogramming leads to KRT80 expression in drug-
resistant BC. We have previously shown that the type II keratin
TAD7 ranked among the most signiﬁcantly epigenetically
reprogrammed TADs when comparing untreated (MCF7, ERα-
positive breast cancer cell lines) non-invasive ET-treated (MCF7
cells resistant to Tamoxifen: MCF7T or Fulvestrant: MCF7F) vs.
invasive AI-resistant BC cell lines7 (MCF7 that were long term
estrogen deprived: LTED cells, and double resistant LTEDT and
LTEDF Fig. 1a, b). ChIP-seq efﬁciencies were rather different
across each cell line but, genome-wide normalization conﬁrmed
that overall, the type II keratin TAD accrues signiﬁcantly more
H3K27ac reads in invasive LTED cells compared with MCF7 and
MCF7T cells (Top 5% for differential9, Fig. 1a inset). Targeted
validation within one of the potential enhancers (E1) using
H3K27ac, H3K4me2, and H3K4me1 conﬁrmed the signiﬁcant
increase of H3K27ac between MCF7 and LTED (Fig. 1c). Type I
and Type II Keratins are the main constituents of cytoplasmic
intermediate ﬁlaments and are involved in crucial cellular pro-
cesses including cell attachment, stress adaptation, and cell
structure maintenance; yet very little is known about their role in
cell movement and metastatic progression. Despite TAD
dynamics, only few keratins within the type II-keratin TAD were
transcriptionally reprogrammed in AI-resistant cell lines, with
KRT80 being the only member which was consistently upregu-
lated in all LTED models, including LTED-derivatives from a
different breast cancer cell line (T47D, Fig. 1a, b and Supple-
mentary Fig. 1a, b). Live-tracking cells during the initial 48 h of
estrogen deprivation shows the absence of substantial prolifera-
tion and/or cell death, suggesting that the majority of cells simply
stall within this time frame (Fig. 1d, ﬂat orange line from 6 to 48
h). Measuring KRT80 transcripts before or after short-term (48 h)
acute estrogen starvation using single cell RNA-seq data shows a
signiﬁcant increase in the proportion of KRT80 positive cells,
strongly suggesting that this increase is driven by de novo tran-
scriptional activation and not selection of KRT80-positive clones
(Fig. 1e). These data were validated in MCF7 and LTED cells
using single cell RNA-FISH (Fig. 1f). As expected, increased
transcription corresponded to increased KRT80 protein level in
both MCF7 and T47D models (Fig. 1g). Interestingly, LTED
cells also show signiﬁcant changes in H3K27ac levels and mRNA
expression for cholesterol biosynthesis genes7, but unexpectedly
the master regulator of cholesterol biosynthesis SREBP111 shows
no transcriptional changes between the two cell types, suggesting
that reprogramming is not driven by transcriptional factor
abundance but rather by its activity7 (Fig. 1f).
KRT80 dynamically changes during breast cancer progression
in vivo. KRT80 is a largely unknown keratin structurally related
to hair keratins12, in contrast with epithelial keratins commonly
found in normal epithelial cells. This led us to further explore the
role of KRT80 in promoting the invasive phenotype developed by
LTED as a consequence of AI-resistance7. KRT80 transcripts
were also elevated in several ERα-negative cell lines, suggesting
that upregulation in drug-resistant cells was not mediated by
changes in ERα activity (Supplementary Data 1). More impor-
tantly, IHC analysis of two independent clinical datasets con-
ﬁrmed that KRT80 positive cells signiﬁcantly increase after AI
treatment while showing a trend in Tamoxifen-treated patients
in vivo13,14 (Fig. 2a). KRT80 localization in vivo was radically
different to what has been shown in conventional keratins (e.g.,
KRT8, KRT14, KRT18, or KRT1915), presenting a peri-nuclear
polarized pattern towards the lumen within healthy ducts and
lobules (Fig. 2b). Similar staining patterns were conserved in
benign lesions (Fig. 2b), whereas KRT80 staining became strongly
cytoplasmic in higher grade BC and metastatic lesions suggesting
a potential role in BC progression (Fig. 2b). Correspondingly,
high KRT80 mRNA levels correlated with poor survival in the
METABRIC ERα-positive BC dataset (Fig. 2c), even more sig-
niﬁcantly when selecting patients that did relapse early and were
treated with endocrine therapies (Fig. 2c). The prognostic role of
KRT80 was then conﬁrmed by multivariate meta-analysis of two
independent datasets with several additional clinical endpoints
(Supplementary Fig. 1c–e and Supplementary Fig. 2). Interest-
ingly, KRT80 was the only reprogrammed Type-II keratin sig-
niﬁcantly associated with clinical endpoints in BC patients
(Fig. 2d).
De novo SREBP1 drives KRT80 activation. Activation of cell
type speciﬁc enhancers has been linked with cancer transcrip-
tional aberration6,16–18, leading us to hypothesize that de novo
enhancer activation within the TAD structure might control
KRT80 expression in AI resistant cells. We used H3K27ac, an
epigenetic mark associated with gene activation6,19, to narrow
down the potential KRT80 enhancers (E1 and E2, Fig. 1b). As
expected, E1-E2 activity was only captured in KRT80-positive
cells (Fig. 1b) while E1 enhancer activity analysis predicted a
signiﬁcant increase in KRT80 positive cells in AI resistant models
(Fig. 1c), in agreement with mRNA and protein analysis (Fig. 1a,
f, g and Supplementary Fig. 3a). 3D meta-analysis from parental
MCF7 ChIA-Pet data strongly suggested that the E1 loci could
contact the KRT80 promoter via enhancer-promoter interactions,
while it excluded the weaker E2 (Supplementary Fig. 3b) sug-
gesting that the 3D interaction is already pre-established in sen-
sitive cells. To test whether E1 drove KRT80 transcriptional
activity in other context, we adapted our recently developed
computational pipeline to measure the relative size of KRT80-
positive clones in several tissues6. This pipeline can estimate the
percentage of cells containing an active enhancer, as at individual
loci the epigenetic signal is a function of the number of mod-
iﬁed nucleosomes6. We thus tested if the estimated size of KRT80
positive cells based on E1 activity in each model is reﬂected at
the transcriptional level. Analysis of Epigenetic Roadmap data
with associated transcriptional proﬁles20 strongly suggested that
increasing E1 positivity, predicting for increasing content of
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KRT80-positive cells, correlates KRT80 transcription levels
(Fig. 3a). E1 activity was also potentially associated with KRT80
transcription in several cell lines (Supplementary Fig. 3c, d). For
example, Keratinocytes ranked as the most clonal KRT80 cell type
and exhibited the highest KRT80 mRNA levels (Supplementary
Fig. 3c, d). Colon cancer HCT116 cells also were predicted to
contain a clonal KRT80 cell population based on E1 activity
(Supplementary Fig. 3c, d). On the other hand, E1 predicts only
for a small subpopulation within normal cells from the large
intestine (Fig. 3a). Interestingly, KRT80 is dramatically upregu-
lated during intestine oncogenesis21 (ranked 4th overall as the
most signiﬁcantly upregulated gene in TCGA normal vs. cecum
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cancer) strongly suggesting a progressive activation of E1 during
colon cancer transformation. E1 also predicts for clonal KRT80
expression in HUVEC cells and HUVEC cells are characterized
by strong KRT80 transcription (Supplementary Fig. 3c, d).
Finally, KRT80 E1 activity also correctly predicted strong
expression in mammary epithelium cells (Supplementary Fig. 3c,
d). Conversely, samples with no E1 activity were found to have no
KRT80 transcription (i.e., immune cells and iPS cells). Overall
these data strongly link E1 to KRT80 transcription. As E1
enhancers span nearly 12.5 Kb, we performed ﬁne-mapping
analysis to narrow down on potential readers. Using our com-
putational pipeline, we sought for E1 sub-regions more strongly
associated with KRT80 expression in our BC cell lines leading to
the identiﬁcation of a core-region within the E1 enhancer (1.5
Kb) (Supplementary Fig. 3a). This core enhancer showed a clear
pattern of activity in actual BC patients6 predicting the existence
of KRT80 clonal and sub-clonal populations in primary and
metastatic BC (Fig. 3b). We next investigated which transcription
factor/s (TFs) might regulate KRT80 expression via core-E1
binding. DHS-seq analysis7 indicated that KRT80 is already
accessible in MCF7 (Fig. 3c), yet digital foot-printing suggested
different occupancy sites (Fig. 3d). Intriguingly, among other
footprints, we noted the appearance of a SREBP1 footprint within
the core-E1 unique to LTED cells. We have previously reported
that AI resistant cells upregulate lipid biosynthesis via global
epigenetic reprogramming7 suggesting widespread SREBP1 acti-
vation in AI resistant cells. However, SREBP1 is not differentially
expressed in LTED cells when compared with parental MCF7
cells (Fig. 1f), suggesting that SREBP1 might upregulate its targets
by increased nuclear shuttling and chromatin binding. This led to
the hypothesis that increased SREBP1 occupancy might drive
KRT80 transcriptional activation in LTED cells. ENCODE TFs
mapping showed that SREBP1 can bind the core-E1 enhancers in
lung cancer cells, the only ENCODE proﬁled cells characterized
by strong KRT80 transcription (Supplementary Fig. 4a, b). To
directly test if SREBP1 drives KRT80 expression in BC we per-
formed ChIP-seq in MCF7 and T47D cells and their respective
AI-resistant models. Our data demonstrate that SREBP1 was
bound at core-E1 only in AI-resistant BC cells (Fig. 3e and
Supplementary Fig. 4c). Interestingly, the expression of KRT80
and SREBP1 target genes was also strongly correlated in BC
patients (Supplementary Fig. 4d). Finally, we show that
SREBP1 silencing abrogated KRT80 expression in LTED cells
(Fig. 3f, g). Overall these data demonstrate an unpredicted link
between SREBP1 and KRT80 activation. Phastcons, PhyloP and
Siphy rates, which measure the rate of DNA conservation
between different species, show a signiﬁcant drop in conservation
at the SREBP1 footprint within the otherwise conserved E1
enhancer (Supplementary Fig. 5), suggesting that the link between
SREBP1 and KRT80 might have evolved relatively recently.
Overall, these data strongly support the hypothesis that the core-
E1 is the critical enhancer driving KRT80 expression in BC cells.
KRT80 directly promotes increased tumor stiffness in vitro
and in vivo. Several studies have investigated how mechanical
stimuli inﬂuence the epigenetic landscape22,23. However, our data
implied a novel causal link whereby epigenetic reprogramming
promoted changes in speciﬁc cytoskeletal components (e.g.,
KRT80) which may ultimately affect the biophysical properties of
cells and tumors24,25 (Figs. 1–3). In agreement, we observed a
signiﬁcant increase in cellular stiffness (inversely correlated to cell
compliance/deformability) at the single cell level after KRT80
over-expression in MCF7 and LTED cells (Fig. 4a). Conversely,
KRT80 depletion in LTED cells resulted in a signiﬁcant loss of
cellular stiffness (Fig. 4a). To test if KRT80 can contribute to
tumor stiffness in vivo we prospectively recruited 20 patients with
suspected BC and performed shear-wave elastography to measure
intra-tumoral stiffness. Elastography was performed prior to
biopsies were taken but all cases were subsequently conﬁrmed
positive breast cancer (Fig. 4b). Our data showed that cancer
lesions had signiﬁcantly higher stiffness than surrounding normal
tissues, with the highest peak of stiffness consistently measured at
the invasive border (Fig. 4b). Interestingly, meta-analysis of
tumor and matched nearby tissue from TCGA show increased
KRT80 mRNA in the tumor biopsies (Supplementary Fig. 6). We
then performed IHC for KRT80 with validated antibodies (Fig. 4c
and Supplementary Fig. 7) using biopsies collected from our
prospective patients. Linear regression analysis showed that
KRT80 positivity signiﬁcantly correlated with intra-tumor stiff-
ness (Fig. 4d). Collectively, these data demonstrate that BCs
characterized with high KRT80 content are mechanically stiffer.
KRT80 upregulation leads to augmented collective invasion.
The effect of increasing stiffness in metastatic invasion is highly
debated. Previous studies have suggested that decreased stiffness,
through loss of keratins, improves single-cell invasion24 typical of
EMT cells. However, solid tumors can also use a myriad of
multicellular invasion programs26 collectively termed “collective
invasion”. Recent studies have shown that keratins such as
KRT14 can play critical roles in collective invasion27 and multi-
clonal metastatic seeding27,28, two processes driving BC pro-
gression27. In addition, a signiﬁcant body of clinical literature has
linked increased breast tumor stiffness to poorer prognosis27,29–31
Fig. 1 AI treatment induces KRT80 expression via epigenetic reprogramming. a Hi-C 3D interactions in GM12878 cells were analyzed using http://
promoter.bx.psu.edu/hi-c/view.php. Data to derive individual TAD were downloaded from http://chromosome.sdsc.edu/mouse/hi-c/download.html. Bars
represent the normalized median change in H3K27ac within the Type II-Keratin TAD compared to the overall change in H3K27ac between parental MCF7
cells (green) and drug-resistant non-invasive (gray) and drug-resistant invasive (orange) counterparts. The bottom heatmap shows the normalized
expression of RNA-seq data for protein coding genes within the Type II-Keratin in all breast cancer cell lines. b Bird-eye view of the H3K27ac proﬁle of the
Type II-Keratins locus. ChIP-seq signal proﬁles from7 are shown across the entire TAD. c Targeted ChIP-qPCR for the E1 enhancer locus using H3K4me1,
H3K4me2 and H3K27ac antibodies. Individual biological replicates, mean and SD are shown. Asterisks represent signiﬁcance at the p < 0.001 level. d Live-
imaging cell counts of mate-labeled MCF7 cells grown in presence or absence of estrogen for 48 h. Dotted line represents an ideal stalling dynamic in cell
number during the time of the assay. Mean and SD of three independent counts are shown. e Population level single-cell RNA-seq data for KRT80
expression are shown. KRT80 was identiﬁed in 10.8% of MCF7 cultured in estrogen rich media and in 39.9% of MCF7 deprived of estrogen for 48 h. The
distribution of the two set of data was compared using a Fisher exact test. Experiments were run comparing cells within 48 h in absence of major cell
division/apoptosis. f Representative single-molecule, single cell RNA-FISH for SREBP1 (red) and KRT80 (green) in MCF7 and LTED cells. g KRT80 protein
levels in MCF7 and additional independent models of invasive drug-resistant breast cancer cell lines. The asterisk represents an unspeciﬁc band.
Acronyms: LTED cells: MCF7 that were long term estrogen deprived; and double resistant; MCF7T, MCF7F, LTEDT, and LTEDF: MCF7 and LTED cells
resistant to Tamoxifen or to Fulvestrant respectively; ETR: endocrine treatment resistant; E2: estrogen; TAD: topological associated domain; RPKM: reads
per kilobase million; KRT: keratin; SREBP1: sterol regulatory element binding protein 1
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and lymph node positivity27,29,30, independently of changes in
extracellular matrix stiffness. We reasoned that a model in which
KRT80 upregulation in BC cells leads to increased stiffness and
augmented collective invasion might reconcile all these observa-
tions. To test this, we developed 3D spheroids from MCF7 or
LTED cells and assessed collective invasion (Fig. 5a) after KRT80
manipulation (Supplementary Fig. 8a–d). Spheroids from
KRT80-positive LTED cells could effectively invade intro matrigel
matrices whereas stable or transient KRT80 depletion completely
abrogated the invasive phenotype (Fig. 5c, d and Supplementary
Fig. 8e, f). Conversely, ectopic expression of KRT80 conferred
matrix invading capacities in otherwise non-invasive MCF7 cells,
even in the absence of chronic estrogen deprivation (Fig. 5b, d).
KRT80 immunostaining showed that KRT80 positive cells
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clustered at the invasive front in LTED spheroids (Fig. 5e and
Supplementary Fig. 9a, b), a pattern reminiscent of the leading
cells characterized in epithelial tumors during collective
invasion27,28. To conﬁrm that invasion was driven by active
motion rather than proliferation at the border of the organoids,
we repeated invasion assays using proliferation sensitive live-
labeling (Fig. 5f). Labeled cells maintained their invasive prop-
erties while KRT80 suppression still blocked invasion (Fig. 5g). As
expected, invading cells retained the dye suggesting that they
actively moved into the matrigel interface in absence of cell
division (Fig. 5h). These data are supported by live-imaging of
organoid invasion performed previously in the same cell lines7.
KRT80 reorganizes cells cytoskeleton to promote lamellipodia
formation. Confocal microscopy analyses informed that LTED
and MCF7-KRT80 cells presented an intricate network of KRT80
ﬁlaments that signiﬁcantly overlap actin ﬁbers (Fig. 6a, b). This
KRT80 network was prominent at the leading edge of cells,
usually localized at or annexed to actin-rich lamellipodium-like
structures (Fig. 6b, asterisk). Conversely, in KRT80low cells (i.e.,
MCF7 and LTED-shA), KRT80 staining was more punctuated
and mainly observed towards the cell cortex, with border cells
presenting strong cortical actin (Fig. 6b, hashtag) and no pro-
minent lamellipodia32. Quantitative analysis of confocal data
showed that KRT80 expression was associated with a signiﬁcant
increase of F-actin at lamellipodial structures, with smaller
compensating changes at the cell cortex and cytosol depending on
the system (i.e., MCF or LTED) (Fig. 6c, d). Importantly, no
signiﬁcant changes were observed in the total F-actin between
MCF7/MCF-KRT80 or LTED/LTED-shKRT80 (Fig. 6d). Toge-
ther, these results suggest that the generation of a network of
KRT80 positive ﬁlaments do not affect actin polymerization but
rather reorganize the actin cytoskeleton to promote lamellipodia
formation. In agreement, cells expressing KRT80 presented a
higher proportion of cells with lamellipodia when compared with
their KRT80low counterparts (Fig. 6e). Focal adhesion growth and
maturation are tightly coupled with the forward movement of the
lamellipodium33, are associated to cell stiffness/cellular
tension29,30, and are particularly relevant in the generation of
forces required for migration and invasion in complex settings. In
line with KRT80 playing a role in these processes, we observed
that KRT80 directly promoted the generation of larger more
mature paxillin focal adhesions, with no signiﬁcant change in the
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number of focal adhesions per cell (Fig. 6f). Interestingly, KRT80
positivity strongly characterized invading cells from prospectively
collected pleural effusion from AI-treated patients (Supplemen-
tary Fig. 9c)33,34.
KRT80 drives cytoskeletal changes involved in migration and
invasion. To test if KRT80 manipulation drives ancillary
phenotypes synergistic to cytoskeletal changes, we performed
RNA-seq in cells transfected with KRT80 but where SREBP1 is
not yet activated (non-invasive MCF7 cells, Fig. 7a). Ectopic
KRT80 expression led to clear transcriptional differences domi-
nated by the reprogramming of a small set of genes (Fig. 7a, b and
Supplementary Data 2). Pathway analyses of upregulated genes
pointed out to cytoskeletal rearrangements (Fig. 7c and
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Supplementary Data 2). Amongst them, we found particularly
striking the strong KRT80-dependent induction of cortactin
(CTTN), a factor directly linked to actin rearrangements, lamel-
lipodia formation and cancer cell invasion34,35, that we conﬁrmed
by immunoﬂuorescence (Fig. 7d). In addition, we also detected a
signiﬁcant upregulation of SEPT9, a member of the septin family
directly linked to actin ﬁber formation, focal adhesion matura-
tion, and motility36,37 (Fig. 7b). Genes activated in response to
KRT80 upregulation have prognostic value, even when other
classical clinical features are considered (Fig. 7e). These data
parallel KRT80 prognostic features and hint that these genes
might underlie early metastatic invasion (Fig. 7e). We also
observed that several genes negatively regulated by KRT80
induction play central roles in cancer biology including negative
regulators of migration (PCDH10, CADM1), tumor suppressors
such as CDKN1A and PDCD2, genes involved in DNA repair
(RAD50), chromatin remodelers as SMARCE1 and CHD4 and
tumor speciﬁc antigens (CD276) suggesting a direct link between
cytoskeletal reprogramming and several other oncogenic pheno-
types (Fig. 7b). Together, these results further support that
KRT80 manipulation is sufﬁcient to activate genes driving dra-
matic cytoskeletal rearrangements that ultimately induce invasive
behaviors in BC and poorer prognosis. We cannot speculate at
the moment if this is driven by a cytoskeleton-transcriptional
feedback or it is mediated by some speciﬁc transcriptional factors.
Discussion
The relationship between drug-resistance and phenotypic repro-
gramming in breast cancer has not been studied in detail, as
generally the focus has been on characterizing the mechanisms of
resistance rather than the associated changes in traits that might
possibly play a role in shifting cancer cell behaviors. Furthermore,
it is known that aberrant cytoskeletal architecture characterizes
tumor cells and it is associated with cell migration and invasion;
yet the endogenous and exogenous triggers underlying cytoske-
letal reorganization in tumor cells are not well understood. Here,
we have uncovered a novel and causal link between endocrine
therapy resistance, intra-tumoral stiffness and augmented inva-
sive potential in luminal BC (Fig. 7f). Our data strongly suggest
that therapy plays a direct role in shaping the biophysical prop-
erties and invasive potential of cancer cells, by inducing epige-
netic rearrangements leading to KRT80 upregulation and
concomitant cytoskeletal reorganization. Our data strongly sug-
gest that SREBP1 is the link between drug-resistance and cytos-
keletal reprogramming. Upon long-term AI treatment, SREBP1
mediates the activation of pro-survival pathways7 by promoting
the cell-autonomous production of endogenous ERα ligands. In
addition, SREBP1 is also recruited at the KRT80 enhancer, a non-
canonical SREBP1 target, leading to KRT80 transcription in drug-
treated cells. This mechanism does not appear to be promoted by
absolute changes in SREBP1 abundance, but rather by enhanced
chromatin binding. Furthermore, it is important to note that our
data demonstrate that SREBP1 is essential but might not be
sufﬁcient for KRT80 activation. How SREBP1 is capable to sense
AI-mediated stress needs to be worked out mechanistically, but
overall these data support SREBP1 as a potential target to
antagonize BC progression. We also describe an unexpected role
for intermediate ﬁlaments in promoting cancer cell invasion by
showing for the ﬁrst time that KRT80 promotes actin cytoske-
leton rearrangements. These are characterized primarily by the
formation of lamellipodia and mature focal adhesions, which are
critical structures required for migration in complex environ-
ments33. Our data might also reconcile some previous observa-
tions that were in an apparent contrast. Few clinical studies have
highlighted that stiffer BC lesions do carry worse prognosis27,29–31,
while others suggested that EMT-like processes, necessarily
decrease intracellular stiffness, are needed for tumor progression.
The link between treatment, KRT80 activation and increased
stiffness would ﬁt with several of these observations, especially in
the light of collective-invasion phenotypes observed for ERα-
positive BC cells27,28. Larger longitudinal clinical studies mea-
suring stiffness and KRT80 activation in endocrine neoadjuvant-
treated patients are needed and should be linked to long-term
monitoring for distal relapse.
A directional link between epigenetic and cytoskeleton repro-
gramming was not described before and it offers an intriguing
axis for drug development and biomarker discovery, especially
within the goal of preventing metastatic invasion in BC patients
treated with aromatase inhibitors.
Methods
Cell lines and cell culture. All cell lines used in the study were karyotyped and
validated and no cell lines from the ICLAC database were used. In this study we
used MCF7 breast adenocarcinoma cell line and derived resistant clones (Sup-
plementary Fig. 1). MCF7 Tamoxifen Resistant cell line (MCF7T) was derived from
MCF7 upon one-year treatment with Tamoxifen. MCF7 Fulvestrant Resistant cell
line (MCF7F) was derived from MCF7 upon one-year treatment with Fulvestrant.
LTED (Long Term Estrogen Deprivation) cell lines were derived from MCF7 cell
line upon one-year estrogen deprivation, mimicking aromatase inhibitor resistance.
LTED Tamoxifen Resistant cells (LTEDT) were derived from LTEDs upon one-
year Tamoxifen treatment. LTED Fulvestrant Resistant cells (LTEDF) were derived
from LTEDs upon one-year Fulvestrant treatment38,39. In addition, we employed
an alternative aromatase inhibitor resistant model: T47D breast adenocarcinoma
cell line and T47D-LTED. The latter was derived from T47D parental upon six
months of estrogen deprivation. MCF7 and T47D breast cancer cell lines were
cultured in DMEM (Sigma-Aldrich) supplemented with 10% FCS (Fetal Calf
Serum, First Link UK), 2 mM L-Glutamine, 100 units/mL penicillin, and 0.1 mg/
mL streptomycin (Sigma). MCF7 were further supplemented with 10-8M Estradiol
(Sigma). Estrogen-deprived cell lines (LTED, LTEDT, and T47D-LTED) were
cultured in phenol-red free DMEM (Gibco, Life Technologies) supplemented with
10% DC-FCS (Double Charcoal stripped Fetal Calf Serum, First Link UK) and 2
mM L-Glutamine, 100 units/mL penicillin, and 0.1 mg/mL streptomycin (Sigma-
Aldrich). LTEDT were further supplemented with 10–7M Tamoxifen (SIGMA).
All cells were tested for mycoplasma contamination using MycoAlert mycoplasma
detection kit Assay Control Set by Lonza (LT07-518) following manufacturer’s
instructions.
Fig. 5 KRT80 directly promotes cell invasion. a Design of the 3D invasion assay. Organoids were derived from treatment naive (green; MCF7) or invasive
AI resistant (orange; LTED) breast cancer cells. KRT80 expression was manipulated via ectopic overexpression or sh-mediated stable depletion. Organoids
were embedded in Matrigel and monitored for 48 h. b Representative brightﬁeld images of KRT80-manipulated organoids. Panels show results obtained in
KRT80 depleted cells. c Representative brightﬁeld images of KRT80-manipulated organoids. Panels show results obtained in KRT80 over-expressing cells
(DKK-tagged KRT80). Small inset number represent normalized fold area changes of each represented experiment. Bars scale= 400 μm. d Quantiﬁcation
of the area fold change in organoids overexpressing KRT80 or KRT80 knock-down LTED cells in 3D invasion assay normalized to MCF7 (*p < 0.05, **p <
0.01, Student t test; n= 3 biological triplicates in which at least 4 organoids were measured). Data is presented as mean ± SD. e Confocal microscopy of
matrigel embedded invasive AI resistant LTED organoids. f Replication dependent labeling of breast cancer spheroids. Cells were labeled with CMFDA that
is converted to its membrane-impermeant ﬂuorescent form by cytosolic esterase to entrap the dye. Active replication can dilute the dye until
disappearance within 2–3 cell cycles. g Quantiﬁcation of the area fold change in organoids treated with CMFDA. Lines represent mean and SD. Asterisks
represent signiﬁcance level p < 0.05 after Student t test. h Representative images of CMFDA tagged spheroids. Invasive borders are highlighted by dotted
white lines. Representative original borders are highlighted by yellow dotted lines. Bars scale= 400 μm
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Generation of stable cell lines. For KRT80 overexpression, a full length KRT80
cDNA clone Myc-DKK-tagged was obtained from OriGene and transformed into
DH5α competent cells (Invitrogen). Plasmid DNA was isolated using Maxi-Prep
Kit (QIAGEN) and transfected in MCF7 and LTED cells using X-tremeGENE 9
DNA Transfection Reagent (Roche) following manufacturer’s instructions.
Transfected cells, carrying Neomycin resistance, were selected with G418 (SIGMA),
used at a ﬁnal concentration of 1 mg/mL for MCF7 and 0.5 mg/mL for LTED.
Knock-down of KRT80 was achieved by transfection of two different shRNA
expression vectors and a scrambled negative control obtained from OriGene. Cells
carrying the corresponding construct were selected with Puromycin (Sigma-
Aldrich) at a ﬁnal concentration of 1 ug/mL for MCF7 and 0.5 ug/mL for LTED cell
line. NucLight Red Lentivirus (IncuCyte, 4627) was used to infect MCF7 and
generate MCF7 mKate2. Stable and polyclonal cell populations were established
after Zeocin selection (300 μg/ml).
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Live cell imaging and data analysis. Live cell imaging was performed on Incu-
Cyte ZOOM (Essen BioScience) equipped with temperature, humidity and CO2
control. Images were acquired every 6 h with 10× plan ﬂuorescence objectives for
the proliferation assay. Data were analyzed and plotted using Prism6. Individual
cells were counted longitudinally to verify absence/presence of proliferation/
cell death.
TAD analysis. TADs were identiﬁed using Hi-C data from IMR90 and H1 stem
cells as described in ref. 7 (http://chromosome.sdsc.edu/mouse/hi-c/download.
html). Acetylation proﬁles were averaged on each TAD locus and difference in
normalized read numbers between TAD loci from MCF7 cells or ET-treated cells
were calculated. Difference were expressed in terms of positive or negative ratios
and ranked according to increase or decrease acetylation7. The Type II Keratin
Locus was identiﬁed within the top 5% of TAD which increase acetylation during
the acquisition of ET-resistance (comparing MCF7 with LTED cells7). In the
current manuscript we have used a similar strategy while comparing MCF7 with
all ET derivatives. Actual averaged read number/TAD are now plotted in Fig. 1a
according to each cell line.
RNA extraction and RT-qPCR. Cells were washed with PBS and harvested using
a cell lifter (Corning) in RLT buffer supplemented with 1% β-mercaptoethanol.
Cell lysate was homogenized using QIAshredder columns (QIAGEN) and RNA
extraction was performed with RNeasy Mini Kit (QIAGEN) following manu-
facturer´s instructions. RNA concentration was measured using a NanoDrop 1000
Spectrophotometer and 0.5–2 μg of RNA were retrotranscribed using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative PCR
(qPCR) was performed using 2× SYBR GREEN Mix (Invitrogen) and expression
levels of each gene were calculated using the 2-ΔΔCt method, normalizing
expression levels to 28S transcript.
Protein extraction, quantiﬁcation, and western blotting. Cells were harvested in
50 μL ice-cold RIPA buffer (50 mM Tris- HCl at pH 8.0, with 150 mM sodium
chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate, and 0.1%
sodium dodecyl sulfate) (Sigma; #R02780), supplemented with 1× protease (Roche;
#11697498001) and 1× phosphatase (Sigma; #93482) inhibitor cocktail. The cell
pellet and RIPA were mixed by pipetting up and down, incubated at 4 oC for 30
min and vortexed every 5 min. Cell lysates were then centrifuged at 13,000 rpm for
30 min at 4 °C. The supernatants were transferred to a new 1.5 mL eppendorf tube
and the pellets were discarded. Protein concentration was measured using BCA
Assay Kit (Thermo Fisher) following manufacturer’s instructions. With regard to
western blotting, 20 μg of protein per sample, were mixed with 4× Bolt sample
buffer (Life Technologies; #B0007), 10× Bolt sample reducing agent (Life Tech-
nologies; #B0009), ddH2O and heated at 95 oC prior to loading. Protein lysate were
loaded into BOLT 4-12% Bis-Tris Plus Gel (Life Technologies; NW04120BOX).
The pre-made gel was placed into a mini gel tank (Life Technologies; #A25977)
containing 1× Bolt running buffer (Life Technologies). Electrophoresis was carried
out at 90 V for 35 min to allow proteins to adequately run through and also until
the bromophenol blue dye reached the bottom of the gels. The gels were transferred
into a Biotrace nitrocellulose membrane (VWR; #PN66485) using a TE-22 transfer
unit (Hoefer GE Healthcare) at 100 V for 90 min. The membrane was incubated in
blocking buffer for 45 min at room temperature to reduce non-speciﬁc binding of
primary antibody. The membrane was then incubated with the diluted primary
antibodies (Anti-KRT80 for cell lines characterization from12, Anti-KRT80 for
shRNA and IHC from HPA 077836 and 077918, Atlas Antibodies (1:200 dilution),
Anti-SREBP1 H-160 sc-8984 Santa Cruz Biotechnology (1:200 dilution), (Guinea
Pig Anti-KRT80 1:5,000; Mouse Anti-DKK 1:1,000, OriGene; Mouse Anti-β-Actin
1:10,000) in blocking buffer at 4 oC and allowed to shake overnight. After primary
antibody incubation, the membrane was washed three times in PBST (5 min per
wash on a rocking platform) and then incubated for 1 h with the HRP-GAPDH
(Abcam; #ab9482 (1:5000 dilution)) conjugated antibody (for the loading control
membrane) which was diluted in 5% BSA/PBST and goat anti-rabbit IgG (H+ L)
Cross Absorbed secondary antibody, HRP 1:20000 dilution (ThermoFisher Sci-
entiﬁc; #31462). The membranes (including the loading control membrane) were
washed three times in PBST. Amersham ECL start Western Blotting Detection
reagent (GE Healthcare Life Sciences; #RPN3243) was used for chemiluminescent
imaging using the Fusion solo (Vilber; Germany) imager.
Chromatin immunoprecipitation (ChIP). For ChIP, cells were ﬁxed with 1%
formaldehyde for 10 min at 37 °C and reaction was quenched with 0.1 M glycine.
The cells were subsequently washed twice with PBS after which they were lysed
in lysis buffer (LB) 1 (50 mM HEPES-KOH, pH 7.5, 40 mM NaCL, 1 mM EDTA,
10% glycerol, 0.5% NP-40, 0.15% Triton X-100), for 10 min, then for 5 min in LB 2
(10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA) and
subsequently eluted in LB 3 for sonication (10 mM TRIS-HCl, pH 8.0, 100 mM
NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, and 0.5%N-laur-
oylsarcosine). DNA was sheared using the Bioruptor® Pico sonication device
(High, 10 cycles of 30” on and 30” off) (Diagenode). Sheared chromatin was cleared
by centrifugation. Magnetic beads were precoated by adding 10 μg of antibody
Rabbit-anti-SREBP1 (H-160): sc-8984 (Santa Cruz Biotechnology, Inc.); Rabbit-
anti-Histone H3 acetyl K27 antibody (abcam, ab4729); Rabbit- anti-Histone H3
(monomethyl K4) antibody (abcam, ab8895); Rabbit- anti-Histone H3 (dimethyl
K4) antibody (abcam, ab7766) to 50 μl magnetic beads per ChIP (Dynabeads
protein A, Life technologies) and incubated for 6 h on a rotating platform at 4 °C.
Diluted sheared chromatin was added to the coated magnetic beads and incubated
on a rotating platform at 4 °C O/N. Ten microliter of sheared chromatin taken as
input and treated the same. The next day magnetic bead complexes were washed
three times with RIPA buffer (50 mM HEPES pH 7.6, 1 mM EDTA, 0.7% Na
deoxycholate, 1% NP-40, 0.5 M LiCL) and two times with TE buffer (10 mM Tris
pH 8.0, 1 mM EDTA). DNA is O/N eluted from the beads in 100 μl de-crosslinking
buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) at 65 °C. After overnight
de-crosslinking, DNA was treated with 2.7 μl of 1 mg/ml RibonucleaseA (RNaseA)
for 30 min at 37 °C and subsequently incubated with 1.3 μl of 20 mg/ml proteinase
K (Invitrogen) for 1 h at 55 °C. Then DNA extraction was performed using SPRI
magnetic beads (Beckman Coulter, B23318). After elution in TE buffer, DNA was
quantiﬁed using Qubit (ThermoFisher Scientiﬁc; Qubit 3.0 Fluorometer; #Q33216)
high sensitivity assay (ThermoFisher Scientiﬁc; #33216). Quantitative polymerase
chain reaction (qPCR) was then carried out (Applied Biosystems; #7900HT Real
time PCR, #StePOnePlus). If sufﬁcient enrichment is seen in the antibody treat-
ment samples over the ‘input’ samples and compared with internal negative con-
trols, these undergo DNA size selection and library preparation.
Library preparation and ChIP-seq data analysis. Prior to sequencing, ChIP
samples were library prepared using the NEBNext Ultra II DNA Library Prep Kit
for Illumina (New England Biolabs, NEBNext Ultra II DNA library prep kit for
Illumina, #E7770, NEBNext Multiplex Oligos for Illumina, #E7335L). Adaptor
ligated DNA was size selected with SPRI magnetic beads (Beckman Coulter,
B23318) which aims to retain DNA fragments between 200–300 base pairs (bp),
recognizable for the Illumina sequencer (#NextSeq500). After library preparation,
we performed qPCR, high sensitivity DNA quantiﬁcation and size selection mea-
surement (Agilent Bioanalyzer 2100 system+High sensitivity DNA measurement
assay; 5067–4626) before sending samples for sequencing. Raw sequencing ﬁles
processed by the Illumina NextSeq500 sequencer were obtained in “FASTQ” for-
mat. The raw sequencing ﬁles were then aligned to the genome using Bowtie
1.11 short reads sequence aligner using the human reference genome 19 (Hg19) as
the reference genome. The output of Bowtie 1.1.1 is the “SAM” ﬁle extension
format, for both input (control) and ChIP samples, which were then used by
Fig. 6 KRT80 induces invasion-associated cytoskeletal changes. a Representative confocal microscopy images showing F-actin (magenta), KRT80 (green)
and DAPI (blue) staining of MCF7-control, MCF7-K80, LTED-control and LTED-sha cells. Scale bars represent 25 μm. b Zoom-up magniﬁcations of areas
indicated in a, showing F-actin (magenta), KRT80 (green) and DAPI (blue) staining in cells located at the border of clusters. Single channel images for F-
actin and KRT80 are also shown. Scale bars, 10 μm. Asterisks indicate lamellipodia-like structures in MCF7-K80 and LTED cells, and hashtags indicate
cortical actin areas in MCF7 and LTED-sha cells. Graphs on the right show line scan analysis for F-actin and KRT80 ﬂuorescence across the leading edges
of cells, as indicated in the broken line in the merged images. c, d Graphs show quantiﬁcation of F-actin ﬂuorescence intensity at lamellipodial regions (c)
and at cell cortex, cytosol and overall (i.e., whole cell) (d) in MCF7-control, MCF7-K80, LTED-control and LTED-sha cells (n= 19, MCF7; n= 20, MCF7-
K80; n= 14, LTED; n= 16, LTED-sha individual cells). e Graph shows quantiﬁcation of percentage of cells with clear lamellipodia and membrane rufﬂes in
MCF7-control, MCF7-K80, LTED-control, LTED-sha and LTED-shb cells (n= 8, MCF7; n= 12, MCF7-K80; n= 12, LTED; n= 7, LTED-sha; n= 6, LTED-shb
ﬁelds of view). f Representative confocal microscopy images showing F-actin (magenta), pY118-Paxillin (green) and DAPI (blue) staining of MCF7-control,
MCF7-K80, LTED-control, LTED-sha and LTED-shb cell. Scale bars, 25 μm. Graphs show quantiﬁcation of individual leading-edge focal adhesion size (left)
and number of adhesions per cell (right). Focal adhesion size (n= 269, MCF7; n= 251, MCF7-K80; n= 257, LTED; n= 331, LTED-sha; n= 276, LTED-shb).
Focal adhesion number (n= 20, MCF7; n= 20, MCF7-K80; n= 20, LTED; n= 20, LTED-sha; n= 20, LTED-shb, individual cells). Statistical analyses were
performed using one-way ANOVA with Tukey’s post-test. Floating bars and lines represent mean, inter-quantile distribution and SD. Asterisks represent
signiﬁcance at *p < 0.05, **p < 0.01 and ***p < 0.001 levels
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Model-based analysis for ChIPSeq (MACS) version 1.42 for peak calling; with all
peaks called at a Q-value cut-off of 10−3 and default settings applied. MACS
outputs result in “BED” ﬁle format and “WIG” ﬁles.
Digital footprinting. Data from digital footprint were obtained from7. Brieﬂy,
DHS-seq libraries were analyzed using Wellington40 with the following parameters:
-fdr 0.01 -pv “−5,−10,−20,−30,−50,−100”, using the DHS called using MACS
v1.4 with a threshold of 1e−10.
RNA sequencing and single cell RNA-seq. Total RNA from each sample was
quantiﬁed by Qubit® Fluorometer and quality checked by Agilent Bioanalyzer®
RNA 6000 Nano Chip. All samples have high quality RNA with a RIN score > 7.
One microgram of total RNA from each sample was used as starting material for
paired-end RNA-seq library preparation using NEBNext rRNA Depletion Kit
(NEB #E6310) and NEBNext Ultra II RNA Library Prep Kit for Illumina (NEB
#E7770) following the manufacturer’s instructions. Libraries were sequenced on an
f
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Fig. 7 KRT80-changes induce transcriptional changes of cytoskeletal genes. a PCA analyses of RNA-seq proﬁled MCF7 breast cancer cells or MCF7 cells
with ectopic expression of KRT80. b Volcano plots of over-expressed or under-expressed genes in MCF7 cells following KRT80 ectopic expression. For a
complete list, see Supplementary Data 2. c Functional enrichment for upregulated genes following KRT80 ectopic expression. d Representative confocal
microscopy images showing F-actin (magenta), cortactin (CTTN, green) and DAPI (blue) staining of MCF7-control and MCF7-K80 cells. Scale bars
represent 25 μm. Graph shows mean ﬂuorescence intensity of cortactin in MCF7-control and MCF7-K80 cells (n= 40, MCF7; n= 4, MCF7-K80 individual
cells). e Kaplan-Meier plot of ERα-positive breast cancer patients dichotomized to average high or low expression for genes upregulated in response to
KRT80 over-expression (Panel b). Multivariate statistics are shown on the right inside table. f Current model: long-term AI treatment promotes
constitutive activation of SREBP1 leading to pro-survival re-activation of estrogen receptor12, and global cytoskeletal re-arrangements. Cytoskeletal re-
organization leads to direct biomechanical changes and promotes pro-invasive behavior
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Illumina Next Seq machine (#NextSeq500). Reads were processed using Kallisto
and DEGS were called using Sleuth41.
For single cell RNA-seq analyses, only cells showing at least 5000 detected
transcripts were considered. Single-cell experiments were performed as described38.
Brieﬂy, cells were processed using 10× genomics platform (v2.3 kits). Barcodes
were demultiplexed using 10× internal pipeline. Expression proﬁles from MCF7
cells either from red media (n= 1227) or two days of estrogen-deprivation (n=
1193) were then normalized using the R package Scran (v1.6.9)42. Differential
expression between the two conditions was estimated using the Two-sample
Likelihood Ratio Test implemented in the LRT function of the MAST R package
(v1.4.1)43.
Single cell RNA-FISH. Cell were cultured, ﬁxed and pretreated according to the
protocol for the RNAscope® Multiplex Fluorescent Reagent Kit v2 Assay provided
by Advanced Cell Diagnostics (ACD, #323100, Nunc Lab Tek II 2 Well Glass
Slides, #154461K). The probes were as follows: RNAscope® 3-plex Positive Control
Probe (320861), RNAscope® Negative Control Probe – Bacillus subtilis dihy-
drodipicolinate reductase (dapB) gene (310043), RNAscope® Target Probe C1
(20ZZ probe named Hs-KRT80 targeting 294-1445 of NM_182507.2, 300031),
RNAscope® Target Probe C2 (RNAscope® Probe - Hs-SQLE 465071, 300031),
RNAscope® Target Probe C2 (20ZZ probe named Hs-SREBF1 targeting 958-2002
of NM_001005291.2, 300031) and RNAscope® Probe - Hs-HMGCR (RNAscope®
Target Probes, 470561). The assay was run following the manufacturer’s instruc-
tions, hybridization was performed overnight. PerkinElmer TSA Plus Fluorophores
(ﬂuorescein, NEL741001KT and Cyanin 3, NEL744001KT) were diluted at 1:1300
and assigned to the channels HRP-C1 and HRP-C2, respectively. Fluorophores:
PerkinElmer TSA Plus Fluorescein System (NEL741001KT) and PerkinElmer
TSA Plus Cyanine 3 System (NEL744001KT). Samples were imaged using a ×60
objective with a Ti Nikon microscope equipped with a spinning disk (CAIRN)
and analysed in Image J.
3D Organoid assay. A total of 250,000 cells were resuspended in 1 mL of the
corresponding media and 20 μL drops were placed in the lid of a 10 cm dish
(Corning). The lid was ﬂipped over the dish containing 5 mL of media in order
to prevent evaporation. Hanging drops were incubated for 5 days at 37% C in a
humidiﬁed atmosphere, during which formation of organoids was achieved. Before
being included in 3D matrix for the invasion assay, the organoids were collected
and labeled with 10 μM CellTracker™ Green CMFDA (Thermo Fisher, Waltham,
USA) dye by incubating them in serum free media for 45 min at 5% CO2. Labeling
solution was removed, and spheroids were washed in cell medium. To follow,
spheroids were centrifuged at 300 rpm, immersed in 10 μL of phenol-red free
Matrigel® (BD Biosciences) and placed in a 24 well-plate (Corning) The appro-
priate media containing G418 or puromycin was subsequently added to the well.
Brightﬁeld images were acquired at days zero and day two using an EVOS
microscope (Advanced Microscopy Group, Life Technologies). Images were ana-
lyzed using Fiji ImageJ software and fold-change area was calculated using the
following formula: Area (fold-change)=Area Day 2/Area Day 0.
Immunoﬂuorescence and confocal microscopy. Organoids were washed with
PBS and ﬁxed for 15 min with 4% PFA/PBS. Fixation was stopped by rinsing with
100 mM Glycine/PBS. Cells were permeabilized with 0.5% Triton/PBS X-100
and unspeciﬁc binding was blocked with blocking solution (5% BSA, 0.2% Triton
X-100, 0.05% Tween in PBS) for 90 min. Organoids were then incubated with
primary antibody (Rabbit Anti-KRT80 1:200, Sigma-Aldrich) for 2 h, washed three
times with washing buffer (0.2% Triton X-100, 0.1% BSA, 0.05% Tween in PBS),
and incubated with secondary antibody (Goat Anti-Rabbit Alexa Fluor 555 1:200,
Invitrogen) for 45 min. Organoids were washed with immunoﬂuorescence buffer
for 20 min and PBS for 10 min. Finally, organoids were mounted in Moviol
(AppliChem) containing 5 μg/mL of DAPI (Lonza) and visualized using a Zeiss
LSM-780 inverted confocal microscope.
Immunoﬂuorescence. Cells were seeded on glass bottom 24 well plates (MatTek)
coated with 10 µg/ml ﬁbronectin (Sigma), ﬁxed in 4% PFA and permeabilized in
PBS with 0.2% Triton X. The samples were blocked in 3% BSA with 0.1% PBS
Tween (PBST) for 3 h. The primary antibodies (Cortactin, 05-180, Millipore, 1:100;
Keratin-80, HPA077836, Sigma Atlas, 1:100; Phospho-Paxillin-pY118, 44-722 g,
Invitrogen, 1:100) were diluted in 3% BSA in 0.1% PBS Tween and incubated
overnight at 4 °C. The wells were then washed 3 times in 3% BSA 0.1% PBST for
10 min, followed by the addition of the appropriate secondary antibody (Alexa
Fluor, Invitrogen), DAPI (Sigma) and FITC-phalloidin (Sigma). Imaging was
performed using Leica SP8 Confocal microscope.
Image analyses. Cells stained for KRT80 and F-actin (Phalloidin) were imaged
with a ×63 oil immersion objective. Cells were assessed for lamellipodia formation
based on morphology and formation of lamellipodial structures. Only cells at the
border of clusters were evaluated. Cells were positive if a clear membrane rufﬂe and
lamellipodia towards the leading edge (i.e., free space) was observed. Values
represent the percentage of positive cells per ﬁeld of view. Analysis of F-actin and
KRT80 ﬂuorescence intensity was performed in confocal images acquired at the
same time at identical laser settings. Analyses of F-actin at different cell regions
were performed using Image J, analyzing 2–3 representative cells at the border of
clusters per image. Areas at the cell cortex, lamellipodia and cytosol were delineated
using the free-hand drawing function and area and mean F-actin ﬂuorescence
intensity measured. To calculate the overall (i.e., whole cell) ﬂuorescence intensity,
the total intensity of cortical, lamellipodial and cytosolic F-actin was calculated and
divided by the total area analyzed. Line scan analyses were generated using the line
intensity function in Leica’s Application Suite X software. The ﬂuorescence
intensity of F-actin and KRT80 as a function of the distance from the cell edge
was obtained from confocal images acquired at the same time at identical laser
settings. Lines (12.5 µm) used for the analysis are indicated in the respective ﬁgures.
Values correspond to the relative ﬂuorescence intensity for each staining.
For analysis of pY118-paxillin adhesion size, cells were imaged using a ×63 oil
immersion objective and analyzed using Volocity (Perkin Elmer). Only cells at
the border of clusters (leading edge) were analyzed. Individual pY118-Paxillin
adhesions towards the leading edge were identiﬁed, selected using the magnetic
lasso tool and the size measured using Volocity. Values represent the mean FA size
in μm2 per cell. For quantiﬁcation of focal adhesion number, individual cells were
identiﬁed and the number of pY118-paxillin adhesions at the leading edge per
cell was manually quantiﬁed.
To determine the mean cortactin (CTTN) ﬂuorescence intensity, cells were
imaged using a ×63 oil immersion objective at the basal plane. Individual cells were
identiﬁed, selected and the mean ﬂuorescence intensity per cell was determined
using Volocity. Values correspond to the mean CTTN ﬂuorescence intensity per
cell for each staining.
Tissue specimens. Seventy-ﬁve human breast specimens and ten metastatic
lymph nodes were selected from Histopathology Department at Charing Cross
Hospital, with the previous approval of Imperial College Healthcare NHS Trust
Tissue Bank.
A Tissue Microarray (TMA) containing 26 primary breast tumors and paired
ETR relapses was constructed as previously described18.
Immunohistochemistry staining was scored using a quick score system by two
independent investigators, one of them a consultant pathologist (SS). Score was
calculated as follows: S= 3 (strongly stained cells), S= 2 (moderate staining), S= 1
(poorly stained cells), and S= 0 (absence of staining). Staining intensity was
assessed as mean intensity from the tumor region contained within the TMA.
A second set of tissues (pre and post-adjuvant therapy) was constructed at the
Istituto Nazionale Tumori (Milan) with material from the INT Tissue Bank. All
specimens were obtained from consented-patients (Imperial College NHS and INT
tissue banks).
Immunohistochemistry. Formalin ﬁxed and parafﬁn embedded (FFPE) tissue
specimens were sliced in 4 μm sections using a Leica RM2235 manual microtome.
Dried sections were de-waxed by immersion in xylene and rehydrated with sub-
sequent immersion in 100% ethanol, 70 % ethanol and distilled water. Antigen
retrieval was performed by immersion in PBS 0.01M citric acid pH 6 and heated at
800W for 15 min. Slides were rinsed in PBS and endogenous peroxidase activity
was blocked for 30 min using Dako RealTM Peroxidase Blocking Solution. Fol-
lowing that, slides were rinsed twice with PBS and incubated with 10% pig serum
(Bio-Rad) for 30 min and overnight with KRT80 antibody (Sigma-Aldrich, 1:200).
Following day, slides were rinsed in PBS and incubated 30 min with secondary
antibody (biotinylated Goat Anti-Rabbit IgG 1:200, Vector Laboratories) and 30
min with an avidin/biotin peroxidase-based system (VECTASTAIN Elite ABC
Kit, Vector Laboratories). Color reaction was developed for 1 min using DAB
(Diaminobenzidine, Vector ImmPACT DAB Peroxidase Substrate). Color devel-
opment was stopped by immersion during 5 min in running tap water and fol-
lowing that, nuclei was stained with haematoxylin. Slides were dehydrated in 100%
ethanol, cleared in xylene and mounted in DPX (SIGMA).
Statistical analysis. Data is presented as mean ± SD (standard deviation) in most
ﬁgures. Whenever this is not the case, the ﬁgure legends states the exact details.
Data analysis was performed using GraphPad Prism 6 software. Statistics are
described in details in each ﬁgure legend. Generally, Student t test and one-way
ANOVA were applied. The sue of additional statistical methods, such as non-
parametric Mann–Whitney test, are described in individual ﬁgure legends.
Survival analysis. Publicly available breast cancer datasets were identiﬁed in GEO
(https://www.ncbi.nlm.nih.gov/geo/), EGA (https://www.ebi.ac.uk/ega/home), and
TCGA (https://cancergenome.nih.gov/). Only cohorts including at least 30 patients
and with available follow-up data were included. Samples derived using different
technological platforms (Affymetrix gene chips, Illumina gene chips, RNA-seq)
were processed independently. For KRT80, the probe set 231849_at was used in the
Affymetrix dataset, the probe ILMN_1705814 was used in the Illumina dataset
and the gene 144501 was used in the RNA-seq dataset. Cox proportional hazards
survival analysis was performed as described previously44. Kaplan–Meier plots
were derived to visualize survival differences. In the multivariate analysis, the RNA
expression of ERα, HER2, and MKI67 were used as surrogate markers for ER and
HER2 status, and for proliferation. In this, the probe sets 205225_at, 216836_s_at,
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and 212021_s_at were used for ERα, HER2, and MKI67, respectively. The survival
analysis was performed for relapse-free survival (RFS), overall survival (OS), and
post-progression survival (PPS). PPS was computed by extracting the RFS time
from the OS time for patients having both RFS and OS data and having an event
for RFS. Censoring data for PPS was derived from the OS event. The survival
analysis was performed in the R statistical environment.
Cellular microrheology. To characterize the mechanical properties of the four
different BC cell lines, we used magnetic tweezer microrheology to measure cell
deformation in response to magnetically generated forces. Tensional magnetic
forces were induced by a high gradient magnetic ﬁeld generated by an electro-
magnetic tweezer device. The positioning of the tip of the magnetic tweezer device
was controlled by an electronic micromanipulator. Superparamagnetic 4.5 µm
epoxylated beads (Dynabeads, Life Technologies) were coated with ﬁbronectin
(40 μg per 8 × 107 beads, Sigma Aldrich F0895) and incubated with adherent cells
for 30 min, prior to measurements, to allow integrin binding and provide a
mechanical link between the bead and the cytoskeleton. The unbound beads were
removed by multiple washing with PBS. The experiments were performed at 37 °C,
5% CO2 and 95% humidity in DMEM containing 2% FΒS in a microscope stage
incubation chamber. A viscoelastic creep experiment was conducted by applying
mechanical tension onto single beads bound on the apical surface of the cells with a
constant pulling force (F0= 1 nN) for 3 s generated by the magnetic tweezers. The
viscoelastic creep response of the cells was recorded by tracking the resulting bead
displacement in brightﬁeld (×40 objective at 20 frames per second, Nikon Eclipse
Ti-B) that is indicative of the local cytoskeletal deformation. A custom-built
MATLAB algorithm was then used to analyze the image sequences and track bead
displacement by following the intensity-weighted centroid of the bead across all
captured frames. The viscoelastic creep response J(t) of cells during force appli-
cation followed a power-law in time J(t)= J0(t/t0)β with the prefactor J0 repre-
senting cell compliance (J0= inverse of cell stiffness in units of kPa−1) and the
dimensionless exponent β representing cell ﬂuidity with values ranging between 0
< β < 1 pure elastic (β= 0) or viscous behavior (β= 1) and with the reference time
t0 was set to 1 s. The creep compliance J(t) represents the ratio (γ(t)/σ0) of the
localized cellular strain γ(t) induced by the applied stress from the magnetic
tweezers σ0, with γ(t) taken as the radial bead displacement normalized over the
bead radius γ(t)= d(t)/r and the applied stress as σ0= F0/4πr2 taken as the applied
force normalized over the bead cross sectional area. Compliance measurements for
each BC cell line were collected from three independent experiments (MCF7 CTRL
n= 60, MCF7 KRT80 n= 34, LTED CTRL n= 41, LTED KRT80 n= 34).
Shearwave elastography. All individuals involved were consented prior to
measurements collection. All SWE was performed by a breast radiologist with more
than 10-years’ experience of performing Breast ultrasound and elastography on
breast lesions. A state-of-the-art ultrasound scanner, Aplio i900 (Canon Medical
Systems, Nasu, Japan) with the latest 2D SWE technology was used for this study.
All SWE maps and calculations were obtained pre-biopsy. A good stand-off was
used for superﬁcial lesions and initially, continuous SWE mode (“multi-shot”) was
used to select the optimum plane and once this was stabilized, a higher energy SWE
push-pulse (“one-shot” mode) was then utilized to obtain the ﬁnal elastogram for
calculations. Regions of interest (ROI) were placed within the center of the lesion,
in the periphery and also within the adjacent normal breast tissue. This has
been stored as raw data within the ultrasound systems which would enable any
re-calculations as necessary.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-seq expression proﬁle can be found at: https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE125128. Single Cell RNA-seq data can be downloaded from ref. 38.
SREBP1 ChIP-seq are available upon request.
Received: 30 July 2018 Accepted: 22 March 2019
References
1. Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping
endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846
(2017).
2. Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors
versus tamoxifen in early breast cancer: patient-level meta-analysis of the
randomised trials. Lancet 386, 1341–1352 (2015).
3. Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape
mechanisms. Nat. Rev. Cancer 3, nrc1075 (2003).
4. Yates, L. R. et al. Genomic Evolution of Breast Caoncer Metastasis and Relapse.
32, 169–184. e7 (2017).
5. Magnani, L. et al. Acquired CYP19A1 ampliﬁcation is an early speciﬁc
mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
Nat. Genet. 49, 444 (2017).
6. Patten, D. K. et al. Enhancer mapping uncovers phenotypic heterogeneity and
evolution in patients with luminal breast cancer. Nat. Med. 24, 1–12 (2018).
https://doi.org/10.1038/s41591-018-0091-x.
7. Nguyen, V. T. et al. Differential epigenetic reprogramming in response to
speciﬁc endocrine therapies promotes cholesterol biosynthesis and cellular
invasion. Nat. Commun. 6, 10044 (2015).
8. Magnani, L. et al. Genome-wide reprogramming of the chromatin landscape
underlies endocrine therapy resistance in breast cancer. Proc. Natl Acad. Sci.
110, E1490–E1499 (2013).
9. Dixon, J. R. et al. Topological domains in mammalian genomes identiﬁed by
analysis of chromatin interactions. Nature 485, 376–380 (2012).
10. Dixon, J. R. et al. Chromatin architecture reorganization during stem cell
differentiation. Nature 518, 331–336 (2012).
11. Horton, J., Goldstein, J. & Brown, M. S. SREBPs: activators of the complete
program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109,
1125–1131 (2002).
12. Langbein, L., Eckhart, L., Rogers, M. A., Praetzel-Wunder, S. & Schweizer, J.
Against the rules: human keratin K80: two functional alternative splice
variants, K80 and K80.1, with special cellular localization in a wide range
of epithelia. J. Biol. Chem. 285, 36909–36921 (2010).
13. Faronato, M. et al. DMXL2 drives epithelial to mesenchymal transition in
hormonal therapy resistant breast cancer through Notch hyper-activation.
Oncotarget 6, 22467 (2015).
14. Magnani, L. et al. The pioneer factor PBX1 is a novel driver of metastatic
progression in ERalpha-positive breast cancer. Oncotarget 6, 21878–218791
(2015).
15. Gusterson, B. A., Ross, D. T., Heath, V. J. & Stein, T. Basal cytokeratins and
their relationship to the cellular origin and functional classiﬁcation of breast
cancer. Breast Cancer Res. 7, 143–148 (2005).
16. Whyte, W. A. et al. Master transcription factors and mediator establish super-
enhancers at key cell identity genes. Cell 153, 307–319 (2013).
17. Morrow, J. J. et al. Positively selected enhancer elements endow osteosarcoma
cells with metastatic competence. Nat. Med. 24, 176–185 https://doi.org/
10.1038/nm.4475 (2018).
18. Akhtar-Zaidi, B. et al. Epigenomic enhancer proﬁling deﬁnes a signature of
colon. Cancer Sci. 336, 736–739 (2012).
19. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine
human cell types. Nature 473, 43–49 (2011).
20. Consortium, R. et al. Integrative analysis of 111 reference human epigenomes.
Nature 518, 317–330 (2015).
21. Li, C. et al. Keratin 80 promotes migration and invasion of colorectal
carcinoma by interacting with PRKDC via activating the AKT pathway.
Cell Death Dis. 9, 1009 (2018).
22. Uhler, C. & Shivashankar, G. Regulation of genome organization and gene
expression by nuclear mechanotransduction. Nat. Rev. Mol. Cell Biol. 18,
717–727 (2017).
23. Le, H. et al. Mechanical regulation of transcription controls Polycomb-
mediated gene silencing during lineage commitment. Nat. Cell Biol. 18,
864–875 (2016).
24. Seltmann, K., Fritsch, A. W., Käs, J. A. & Magin, T. M. Keratins signiﬁcantly
contribute to cell stiffness and impact invasive behavior. Proc. Natl Acad. Sci.
USA 110, 18507–18512 (2013).
25. Karantza, V. Keratins in health and cancer: more than mere epithelial cell
markers. Oncogene 30, 127–138 (2010).
26. Friedl, P. & Alexander, S. Cancer invasion and the microenvironment:
plasticity and reciprocity. Cell 147, 992–1009 (2011).
27. Cheung, K. J., Gabrielson, E., Werb, Z. & Ewald, A. J. Collective invasion
in breast cancer requires a conserved basal epithelial program. Cell 155,
1639–1651 (2013).
28. Cheung, K. J. et al. Polyclonal breast cancer metastases arise from collective
dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl Acad.
Sci. 113, E854–E863 (2016).
29. Evans, A. et al. Invasive breast cancer: relationship between shear-wave
elastographic ﬁndings and histologic prognostic factors. Radiology 263,
673–677 (2012).
30. Youk, J., Gweon, H. & Son, E. Shear-wave elastography in breast
ultrasonography: the state of the art. Ultrasonography 36, 300–309 (2017).
31. Acerbi, I. et al. Human breast cancer invasion and aggression correlates
with ECM stiffening and immune cell inﬁltration. Integr. Biol. 7, 1120–1134
(2015).
32. Eddy, R. J., Weidmann, M. D., Sharma, V. P. & Condeelis, J. S. Tumor cell
invadopodia: invasive protrusions that orchestrate metastasis. Trends. Cell
Biol. 27, 595–607 (2017).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09676-y
14 NATURE COMMUNICATIONS |         (2019) 10:2115 | https://doi.org/10.1038/s41467-019-09676-y | www.nature.com/naturecommunications
33. Parsons, T. J., Horwitz, A. & Schwartz, M. A. Cell adhesion: integrating
cytoskeletal dynamics and cellular tension. Nat. Rev. Mol. Cell Biol. 11, 633
(2010).
34. Yamaguchi, H. & Condeelis, J. Regulation of the actin cytoskeleton in cancer
cell migration and invasion. Biochimica Et Biophysica Acta 1773, 642–652
(2007).
35. Schnoor, M., Stradal, T. E. & Rottner, K. Cortactin: cell functions of a
multifaceted actin-binding protein. Trends Cell Biol. 28, 79–98 (2018).
36. Gonzalez, M. E. et al. High SEPT9_v1 expression in human breast cancer
cells is associated with oncogenic phenotypes. Cancer Res. 67, 8554–8564
(2007).
37. Dolat, L. et al. Septins promote stress ﬁber–mediated maturation of focal
adhesions and renal epithelial motility. J. Cell Biol. 207, 225–235 (2014).
38. Hong, S. et al. Single-cell Transcriptomics reveals multi-step adaptations to
endocrine therapy. Preprint at Biorxiv https://www.biorxiv.org/content/
10.1101/485136v1 (2018).
39. Shaw, L. E., Sadler, A. J., Pugazhendhi, D. & Darbre, P. D. Changes in
oestrogen receptor-α and -β during progression to acquired resistance to
tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast
cancer cells. J. Steroid Biochem. Mol. Biol. 99, 19–32 (2006).
40. Piper, J. et al. Wellington: a novel method for the accurate identiﬁcation of
digital genomic footprints from DNase-seq data. Nucleic Acids Res. 41,
e201–e201 (2013).
41. Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential
analysis of RNA-seq incorporating quantiﬁcation uncertainty. Nat. Methods
14, 687–690 (2017).
42. Lun, A., McCarthy, D. J. & Marioni, J. C. A step-by-step workﬂow for low-
level analysis of single-cell RNA-seq data. F1000Res. 5, 2122 (2016).
43. Finak, G. et al. MAST: a ﬂexible statistical framework for assessing
transcriptional changes and characterizing heterogeneity in single-cell RNA
sequencing data. Genome. Biol. 16, 278 (2015).
44. Mihály, Z. et al. A meta-analysis of gene expression-based biomarkers
predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer
Res. Tr. 140, 219–232 (2013).
Acknowledgements
We want to acknowledge and thank all patients and their families for the support and for
donating the research samples. We thank Giacomo Corleone, Sung Pil Hong, Iros
Barozzi, and Carlos Matellan for the technical assistance. The authors gratefully
acknowledge infrastructure support from the Cancer Research UK Imperial Centre, the
Imperial Experimental Cancer Medicine Centre and the National Institute for Health
Research Imperial Biomedical Research Centre. L.M. was supported by a CRUK fel-
lowship (C46704/A23110). Y.P. was supported by a CRUK Studentship (PS2099). A.J.F.
and F.C. are funded by the Institute of Cancer Research, London (UK). F.C. is also
funded by Worldwide Cancer Research (Grant 15-0273), Cancer Research UK (C57744/
A22057) and the Ramon y Cajal Research Program (MINECO, RYC-2016-20352).
We acknowledge Z. Magnani for his constructive comments on the manuscript.
Author contributions
L.M. conceived the study. Y.P., A.J.F., A.R.M., A.U., A.C., P.M., M.F., C.D., J.H.C.
performed all the experiments and analyses, A.L. performed Shearwave elastography,
L.M., B.G., and F.C. performed analyses, S.S., G.P., and C.C. provided samples, A.U.,
L.M., and G.P. scored pathology sections, A.C. and A.R.H. performed stiffness mea-
surements in cells, C.I. identiﬁed, collected and analyzed patient’s samples. A.U., C.D.,
J.H.C., and N.P. performed tissue staining. L.M. and F.C. wrote the manuscript with
contribution from all authors. All authors approved the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09676-y.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications thanks Cyril Esnault and the other
anonymous reviewers for their contribution to the peer review of this work. Peer reviewer
reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09676-y ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2115 | https://doi.org/10.1038/s41467-019-09676-y |www.nature.com/naturecommunications 15
